Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
Alok Chandra, Ravi Kanth, Sandeep Thareja Department of Gastroenterology, Base Hospital, New Delhi, IndiaCorrespondence: Ravi KanthDepartment of Gastroenterology, Base Hospital, New Delhi, IndiaEmail ravikanthf2@gmail.comBackground: Adalimumab (ADA) is approved for the management of lcerative coliti...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2019-11-01
|
| Σειρά: | Biologics: Targets & Therapy |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.dovepress.com/efficacy-and-safety-of-adalimumab-biosimilar-exemptia-in-moderate-to-s-peer-reviewed-article-BTT |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|